Prosecution Insights
Last updated: April 19, 2026
Application No. 18/678,376

DNA-BASED ADAPTOME PROFILING FOR MINIMAL RESIDUAL DISEASE QUANTIFICATION IN LYMPHOID MALIGNANCIES

Final Rejection §112
Filed
May 30, 2024
Examiner
HORTH, LISA ANNE
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Milaboratories Inc.
OA Round
4 (Final)
66%
Grant Probability
Favorable
5-6
OA Rounds
3y 1m
To Grant
96%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allow Rate
21 granted / 32 resolved
+5.6% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
33 currently pending
Career history
65
Total Applications
across all art units

Statute-Specific Performance

§101
10.2%
-29.8% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
13.4%
-26.6% vs TC avg
§112
46.4%
+6.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 32 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status Claims 1,4-13,15-17,19-24 are currently pending. Claims 2,3,14 and 18 have been cancelled. Any rejection or objection not reiterated herein has been overcome by amendment. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 4 is indefinite in the recitation of “wherein the k-mers have a length of at least 16 bases”. The scope of the claim is unclear since claim 1 does not reference k-mers. There is also insufficient antecedent basis for the limitation “the k-mers”. Claim 7 depends from claim 4 and is rejected for the same reason. Claim 5 is indefinite in the recitation of “from the clusters identified…”. The scope of the claim is unclear since claim 1 does not recite “clusters identified”. A clustering algorithm is disclosed to correct for PCR and sequencing errors to assemble rearrangement clonotypes and/or incomplete rearrangement clonotypes. Claim 6 and 8 depend from claim 5 and are rejected for the same reason. Response to Remarks: It is noted that all comments relate to withdrawn rejections or other acceptable amendments. Conclusion Claims 1, 9-13,15-17, 19, 24 are free of the art and claims 4-8 are rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa Horth whose telephone number is (703)756-4557. The examiner can normally be reached Monday-Friday 8-4 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LISA HORTH/Examiner, Art Unit 1681 /GARY BENZION/Supervisory Patent Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

May 30, 2024
Application Filed
Sep 07, 2024
Non-Final Rejection — §112
Dec 30, 2024
Response Filed
Feb 07, 2025
Final Rejection — §112
May 30, 2025
Response after Non-Final Action
Jul 10, 2025
Non-Final Rejection — §112
Jan 13, 2026
Response Filed
Feb 09, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12571032
POLYMERASE-TEMPLATE COMPLEXES
2y 5m to grant Granted Mar 10, 2026
Patent 12559785
Analyte Enrichment Methods and Compositions
2y 5m to grant Granted Feb 24, 2026
Patent 12559794
METHOD FOR NUCLEIC ACID AMPLIFICATION
2y 5m to grant Granted Feb 24, 2026
Patent 12534766
RAPID DETECTION OF ANTIMICROBIAL RESISTANCE BY MICROBIAL RIBOSOME IMMUNOPRECIPITATION
2y 5m to grant Granted Jan 27, 2026
Patent 12517111
SYSTEMS AND METHODS FOR IDENTIFYING AND ISOLATING INVASIVE SUBPOPULATIONS OF CANCER CELLS IN REAL-TIME
2y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
66%
Grant Probability
96%
With Interview (+30.4%)
3y 1m
Median Time to Grant
High
PTA Risk
Based on 32 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month